Login / Signup

Economic evaluation of direct-acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore.

Yu Jun WongMcVin Hh CheenJohn C HsiangRahul KumarJessica TanEng K TeoPrem H Thurairajah
Published in: JGH open : an open access journal of gastroenterology and hepatology (2019)
At current price, DAA as first-line therapy is not cost-effective compared with PR in GT3 HCV patients in Singapore.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • hepatitis c virus
  • stem cells
  • human immunodeficiency virus
  • replacement therapy
  • smoking cessation